- Home
- NKE vs MRNA Comparison
NKE vs MRNA Comparison
Compare NKE & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NKE | MRNA |
|---|---|---|
| Founded | 1964 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9B | 61.6B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NKE | MRNA |
|---|---|---|
| Price | $35.22 | $189.20 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 42 | 23 |
| Target Price | $45.63 | ★ $119.56 |
| AVG Volume (30 Days) | ★ 26.1M | 11.7M |
| Earning Date | 10-01-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $46,398,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | N/A | $8.05 |
| Revenue Next Year | $3.25 | $16.07 |
| P/E Ratio | $17.03 | ★ N/A |
| Revenue Growth | 0.19 | ★ 4.29 |
| 52 Week Low | $35.21 | $22.28 |
| 52 Week High | $74.78 | $208.90 |
Technical Indicators
Market Signals| Indicator | NKE | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 37.54 | 69.29 |
| Support Level | N/A | $43.35 |
| Resistance Level | $37.04 | N/A |
| Average True Range (ATR) | 0.81 | 10.80 |
| MACD | 0.12 | 0.77 |
| Stochastic Oscillator | 32.08 | 76.61 |
Price Performance
Historical ComparisonAbout NKE Nike Inc.
Nike is the largest athletic footwear and apparel brand in the world. Footwear generates about two-thirds of its sales. Key performance footwear categories include basketball, running, and football (soccer). Its brands include Nike, Jordan (premium athletic footwear and clothing), NikeSkims (women's athleisure), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores (including about 5,500 in China), and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.